Protara Therapeutics, Inc.
NASDAQ:TARABiotechnology
-$0.05 today
- Market cap
- $144.07M
- Beta
- 1.45
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.48
Volume 1.15M
Average 0.73M
TARA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Protara Therapeutics, Inc.NASDAQ: TARA
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$17.69M, compared with -$11.83M a year earlier. Trailing-twelve-month EBITDA was -$62.94M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -28.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$17.69M-2.8% QoQ
- Last fiscal yearDec 2025
- -$57.08M-28.9% YoY
- LTMMar 2026
- -$62.94M-39.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -49.5% | +100.0% | +149.5 pp |
| 1 year | -28.9% | +100.0% | +128.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (57.08M) USD
- Year-over-year change
- -28.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (57.08M) | -28.9% |
| FY2024 | 2024-12-31 | (44.26M) | -10.4% |
| FY2023 | 2023-12-31 | (40.08M) | +37.9% |
| FY2022 | 2022-12-31 | (64.57M) | -42.2% |
| FY2021 | 2021-12-31 | (45.4M) | — |
EBITDA vs competitors
How TARA compares with its peers on the latest reported figures
- TARA's LTM Mar 2026 EBITDA of -$62.94M is the 7th highest of the 10 companies compared; the peer median is -$35.76M.
- Its year-over-year change of -39.6% is the 7th highest of 9, against a peer median of +31.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$14.84M | +39.0% | — | 102.5% | |
| LTM Mar 2026 | -$22.06M | +62.9% | — | 28.2% | |
| LTM Mar 2026 | -$33.82M | +24.4% | — | 117.0% | |
| LTM Mar 2026 | -$35.22M | — | — | — | |
| LTM Sep 2026 | -$35.76M | -89.6% | — | — | |
| LTM Mar 2026 | -$52.72M | +20.1% | — | 161.1% | |
| LTM Mar 2026 | -$62.94M | -39.6% | — | — | |
| LTM Mar 2026 | -$75.72M | +45.7% | — | 135.5% | |
| LTM Mar 2026 | -$76.13M | +39.6% | — | 455.3% | |
| LTM Mar 2026 | -$117.46M | -66.2% | — | 339.9% | |
| Peer median (excluding TARA) | -$35.76M | +31.7% | — | 135.5% | |
Competitors are the stored peer set for TARA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 341K | 0 | 362K |
| Gross Profit | 0 | 0 | (341K) | 0 | (362K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 21.09M | 16.81M | 24.79M | 31.7M | 42.63M |
| Selling, General & Admin | 26.4M | 20.74M | 18.62M | 17.45M | 21.92M |
| Operating Expenses | 47.49M | 67.06M | 43.27M | 49.15M | 64.19M |
| Depreciation & Amortization | 117K | 248K | 341K | 332K | 362K |
| EBITDA | (45.4M) | (64.57M) | (40.08M) | (44.26M) | (57.08M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (47.49M) | (67.06M) | (43.61M) | (49.15M) | (64.55M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 237K | 1.11M | 2.73M | 4.14M | 6.33M |
| Interest Expense | 1.74M | 1.14M | 0 | 0 | 0 |
| Other Income / Expenses | 237K | 1.11M | 3.19M | 4.56M | 7.11M |
| Income Before Tax | (47.25M) | (65.95M) | (40.42M) | (44.6M) | (57.44M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (47.25M) | (65.95M) | (40.42M) | (44.6M) | (57.44M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (4.20) | (5.86) | (3.57) | (2.17) | (1.34) |
| EPS (Diluted) | (4.20) | (5.86) | (3.57) | (2.17) | (1.34) |
| Weighted Avg Shares | 11.23M | 11.26M | 11.33M | 20.59M | 42.84M |
| Weighted Avg Shares (Diluted) | 11.23M | 11.26M | 11.33M | 20.59M | 42.84M |
Protara Therapeutics, Inc.
NASDAQ:TARA
Intrinsic Alpha fair value
Locked
Current Price
$2.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.